42ef6344-2fdd-4c39-9b98-0c1e3ccbc487.pdf


Telesta Therapeutics

(Toronto Stock Exchange:TST)


Transforming the Bladder Cancer Treatment Landscape

Focus on MCNA Approval & Launch


Safe Harbour Statement

This presentation contains forward-looking statements about Telesta Therapeutics' business objectives, strategies and outlooks that involve risks and uncertainties. These statements are 'forward- looking' because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward- looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. A detailed description of the risks that could cause actual events or results to materially differ from our current expectations can be found in our public filings available at www.sedar.com. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.


2


Telesta Therapeutics

  • Focused on MCNA - a biologic therapeutic for 2nd line treatment of high risk refractory/relapsing non-muscle invasive bladder cancer

    • Significant unmet medical need

  • Submitted Biologics License Application (BLA) with FDA on June 30, 2015

    • Designated for Priority Review - August 27, 2015

    • Advisory Committee (AdComm) meeting - November 18, 2015

    • PDUFA date - February 27, 2016

  • Building a targeted U.S. commercial infrastructure

  • Global (ex-U.S., ex-Japan) license with Ipsen on October 28,

    2015

    • Seeking Japanese partner

  • Fully funded business plan


Non-Confidential 3

Leadership Team


Dr. Michael Berendt

CEO & Chief Scientist

Senior Executive Roles: Pharma (Bayer, Pfizer), Venture Capital (AEA, RCT) Biotech (Aegera Therapeutics); Boards: Waters Corp (NYSE:WAT), Anchor Therapeutics (Chair), Alethia Biotherapeutics (Chair), Neomed Institute


Donald Olds

Chief Operating Officer

Senior Executive Roles: Biotech (Aegera Therapeutics), IT, Telecom, Investment Banking (TD Securities); Boards: Neomed Institute (Chair), Oxfam Quebec (Chair)


Brian Ford

Chief Financial Officer

Senior Executive Roles - Finance & Consulting: Ernst & Young (EY)

Monique Champagne Vice President, Clinical Research

Leadership Roles: Clinical Research & Development - Biotech, CROs, Pharma: Xanthus, Supratek, Quintiles, Wyeth- Ayerst, Scat


Dr. Mathieu Boudreau Vice President, Corporate Development & Licensing

Leadership Roles, Corporate/Business Development - Specialty Pharma & Biotech: Pendopharm, Pharmascience, Aegera Therapeutics

Brian Groch

Chief Commercial Officer

Leadership Roles: Commercial Operations, Market Access, Marketing

& Sales - Specialty Pharma/ Pharma:

Horizon Pharma, Exsto, Dendreon, Novartis, Merck & Co.


Non-Confidential 4

distributed by